OGN Quote, Financials, Valuation and Earnings

Amgen has a net margin of 6.85% compared to Organon &'s net margin of 6.9%. Organon &'s return on equity of 397.42% beat Amgen's return on equity of 66.87%.

Organon & has a consensus price target of $20.00, signalling upside risk potential of 78.89%. On the other hand Amgen has an analysts' consensus of $316.99 which suggests that it could grow by 11%. Given that Organon & has higher upside potential than Amgen, analysts believe Organon & is more attractive than Amgen.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amgen has a beta of 0.583, suggesting its less volatile than the S&P 500 by 41.682%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 10.02%. Amgen offers a yield of 3.19% to investors and pays a quarterly dividend of $2.38 per share. Organon & pays 34.38% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

Organon & quarterly revenues are $1.6B, which are smaller than Amgen quarterly revenues of $9.1B. Organon &'s net income of $109M is lower than Amgen's net income of $627M. Notably, Organon &'s price-to-earnings ratio is 3.36x while Amgen's PE ratio is 37.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.45x versus 4.62x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

Biogen has a net margin of 6.85% compared to Organon &'s net margin of 10.87%. Organon &'s return on equity of 397.42% beat Biogen's return on equity of 10.33%.

Organon & has a consensus price target of $20.00, signalling upside risk potential of 78.89%. On the other hand Biogen has an analysts' consensus of $196.47 which suggests that it could grow by 70.59%. Given that Organon & has higher upside potential than Biogen, analysts believe Organon & is more attractive than Biogen.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 10.02%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.6B, which are smaller than Biogen quarterly revenues of $2.5B. Organon &'s net income of $109M is lower than Biogen's net income of $266.7M. Notably, Organon &'s price-to-earnings ratio is 3.36x while Biogen's PE ratio is 10.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.45x versus 1.74x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of 6.85% compared to Organon &'s net margin of 1.4%. Organon &'s return on equity of 397.42% beat Bruker's return on equity of 6.78%.

Organon & has a consensus price target of $20.00, signalling upside risk potential of 78.89%. On the other hand Bruker has an analysts' consensus of $63.21 which suggests that it could grow by 63.07%. Given that Organon & has higher upside potential than Bruker, analysts believe Organon & is more attractive than Bruker.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.426%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 10.02%. Bruker offers a yield of 0.52% to investors and pays a quarterly dividend of $0.05 per share. Organon & pays 34.38% of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.6B, which are larger than Bruker quarterly revenues of $979.6M. Organon &'s net income of $109M is higher than Bruker's net income of $13.7M. Notably, Organon &'s price-to-earnings ratio is 3.36x while Bruker's PE ratio is 51.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.45x versus 1.72x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 6.85% compared to Organon &'s net margin of -2357.27%. Organon &'s return on equity of 397.42% beat Palatin Technologies's return on equity of --.

Organon & has a consensus price target of $20.00, signalling upside risk potential of 78.89%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Organon &, analysts believe Palatin Technologies is more attractive than Organon &.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 10.02%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.6B, which are larger than Palatin Technologies quarterly revenues of $350K. Organon &'s net income of $109M is higher than Palatin Technologies's net income of -$2.4M. Notably, Organon &'s price-to-earnings ratio is 3.36x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.45x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.